New insulin analog provides mealtime glucose control

Article

The FDA recently approved insulin glulisine [DNA origin](Apidra, Aventis Pharmaceuticals) for the control of hyperglycemia in adult patients with diabetes mellitus. According to the manufacturer, insulin glulisine should be used in regimens that include a longer-acting insulin or basal insulin analog. Aventis recently announced that it will delay the launch of insulin glulisine until after the approval of its OptiClick pen delivery device

Related Content
© 2024 MJH Life Sciences

All rights reserved.